secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001628280-24-008045
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks FY2023 revenue $251M (-47% YoY); guides FY2024 total revenue $215-235M
--------------------------------------------------------------------------------

- Cell Engineering services revenue $139M (+31% YoY); added 78 new Cell Programs in 2023.
- Biosecurity revenue $108M (-68% YoY) as K-12 testing ramped down; shifting to recurring model.
- Q4 2023 total revenue $35M (-65% YoY); Q4 Adj. EBITDA loss $(96)M vs. $(76)M prior year.
- Cash balance $944M; FY2024 guidance: 100-120 new Cell Programs; total revenue $215-235M.
- Acquired Patch Biosciences, Proof Diagnostics, Reverie Labs; launched Technology Network of 25+ partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828024008045/0001628280-24-008045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828024008045/dna-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-008045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer